🕷️ Crawler Inspector

URL Lookup

Direct Parameter Lookup

Raw Queries and Responses

1. Shard Calculation

Query:

Response:

Calculated Shard: 79 (from laksa109)

2. Crawled Status Check

Query:

curl -X POST \
  'http://laksa079.int.ahrefs:8124/' \
  -H 'Content-Type: text/plain' \
  -H 'X-ClickHouse-Database: crawler3' \
  -H 'Authorization: Basic YXBpOg==' \
  -d 'SELECT getAhrefsURLFromUnparsed(src_unparsed) AS found_url, ifNull(toUnixTimestamp(download_stamp), 0) AS crawl_time, ifNull(toUnixTimestamp(props_url_first_seen), 0) AS first_indexed_time, download_http_code AS http_code, src_unparsed AS src_unparsed, src_root_hash AS src_root_hash, history_drop_reason AS history_drop_reason, meta_title AS meta_title, meta_descriptions AS meta_descriptions, attrs_boilerpipe_text AS attrs_boilerpipe_text, attrs_markdown AS attrs_markdown, attrs_readable_markdown AS attrs_readable_markdown, meta_canonical AS meta_canonical FROM crawler3.page_info_local FINAL PREWHERE (src_root_hash, src_unparsed) IN ((getAhrefsRootHashFromUnparsed(getAhrefsUnparsedNoserviceFromURL(\'https://fortune.com/2022/02/14/novavax-covid-19-vaccine-approval-singapore-us-fda/\')), getAhrefsUnparsedNoserviceFromURL(\'https://fortune.com/2022/02/14/novavax-covid-19-vaccine-approval-singapore-us-fda/\'))) FORMAT JSONEachRow'

Response:

{"found_url":"https:\/\/fortune.com\/2022\/02\/14\/novavax-covid-19-vaccine-approval-singapore-us-fda\/","crawl_time":1774300362,"first_indexed_time":1644824393,"http_code":200,"src_unparsed":"com,fortune!\/2022\/02\/14\/novavax-covid-19-vaccine-approval-singapore-us-fda\/ s443","src_root_hash":"13809836321913650279","history_drop_reason":null,"meta_title":"Singapore approves Novavax COVID vaccine while U.S. FDA reviews application | Fortune","meta_descriptions":["Singapore's green light adds to a string of approvals for the U.S.-based vaccine maker."],"attrs_boilerpipe_text":"On Monday, Singapore approved the COVID vaccine from U.S. vaccine maker Novavax for adults over age 18, making the city-state the latest country to give the go-ahead to Novavax’s protein-based jab.\nNovavax’s approval in Singapore follows a string of regulatory victories for the American firm, which has racked up approvals with the World Health Organization and\nEuropean Medicines Agency\nand individual countries like\nAustralia\n, the U.K., and South Korea since late last year.\nSingapore’s government says it expects shipments of the jab to arrive within “the next few months.” It approved the jab based on clinical data that demonstrated up to 90% efficacy in preventing COVID-19 infections and 100% efficacy in preventing deaths. Singapore’s government said Novavax has not provided data on how the vaccine performs against Delta and Omicron variants, but it believes that the vaccine will continue to maintain efficacy against the more recent variants.\n“[Novavax’s] vaccine meets [Singapore’s] quality, safety, and efficacy standards, and the benefits outweigh the risks for the Singapore population,” a press release said.\nIn its vaccination drive, Singapore has deployed mRNA vaccines from Moderna and Pfizer as well as an inactivated jab from Chinese maker Sinovac. Singapore is also one of the\nmost vaccinated\ncountries in the world, with 84.8% of its population fully vaccinated and 57.6% of its population boosted. The U.S., by contrast, has fully vaccinated 63.8% of its population and boosted 27.3% of people, according to\nBloomberg\n.\nNovavax’s protein-based COVID jab works\nslightly differently\nfrom the mRNA jabs of\nPfizer\nand\nModerna\n. Novavax’s vaccine inserts noninfectious spike proteins into the body to induce an immune response. The mRNA jabs teach the body to make its own spike proteins to ward off infections.\nManufacturing and regulatory delays\nplagued\nNovavax for much of last year, but the company’s alternative, protein-based vaccine technology has nonetheless inspired\na group of fans\nto wait to get the vaccine as a primary dose or booster shot, even though—in many cases—they’ve had access to other vaccines for months.\n“Despite high vaccination rates in Australia, there has been a demand for a protein-based formula,” Greg Hunt, Australia’s minister of health, said in a statement about rolling out\nNovavax’s vaccine this week\n. “For some people, the arrival of Novavax will be the extra push they need to get their first jab and kick-start their protection against COVID-19.”\nIn the U.S., Novavax submitted its final paperwork to the Food and Drug Administration on Jan. 31, and Novavax CEO Stanley Erck recently said he expects\nfeedback from the FDA this month\n. Novavax also announced last Thursday that its vaccine proved 80% effective in a Phase III trial among 12- to 17-year-olds at a time when the Delta variant was dominant in the U.S., which may help the firm get its jab into the arms of younger populations.\n“We believe the Novavax vaccine offers a differentiated technology and option for this younger population given its established protein-based technology already used in other vaccines, and the positive responses demonstrated against variants,” Filip Dubovsky, Novavax’s chief medical officer, said in a\npress release\n.","attrs_markdown":"Search\n\n[Subscribe for \\$1Subscribe for \\$1](https:\/\/fortune.com\/subscribe\/?itm_source=Site_0_HCL_NAV_CTA_0_2025_ZZ&redirect=%2F2022%2F02%2F14%2Fnovavax-covid-19-vaccine-approval-singapore-us-fda%2F)\n\n[Sign in](https:\/\/fortune.com\/signin\/?signin_redirect=%2F2022%2F02%2F14%2Fnovavax-covid-19-vaccine-approval-singapore-us-fda%2F)\n\n- [Home](https:\/\/fortune.com\/)\n- [Latest](https:\/\/fortune.com\/section\/latest\/)\n- [Fortune 500](https:\/\/fortune.com\/section\/fortune-500\/)\n- [Finance](https:\/\/fortune.com\/section\/finance\/)\n- [Tech](https:\/\/fortune.com\/section\/tech\/)\n- [Leadership](https:\/\/fortune.com\/section\/leadership\/)\n- [Lifestyle](https:\/\/fortune.com\/section\/lifestyle\/)\n- [Rankings](https:\/\/fortune.com\/ranking\/)\n- [Multimedia](https:\/\/fortune.com\/2022\/02\/14\/novavax-covid-19-vaccine-approval-singapore-us-fda\/)\n\n[COVID-19 vaccines](https:\/\/fortune.com\/tag\/covid-vaccine\/)\n\n# Singapore is the latest country to approve Novavax’s COVID vaccine while the U.S. reviews application\n\n![Grady McGregor](https:\/\/content.fortune.com\/wp-content\/uploads\/2020\/09\/placeholder_16x9.jpg)\n\nBy\n\n[Grady McGregor](https:\/\/fortune.com\/author\/grady-mcgregor\/)\n\nGrady McGregor\n\n![Grady McGregor](https:\/\/content.fortune.com\/wp-content\/uploads\/2020\/09\/placeholder_16x9.jpg)\n\nBy\n\n[Grady McGregor](https:\/\/fortune.com\/author\/grady-mcgregor\/)\n\nGrady McGregor\n\nFebruary 14, 2022, 1:36 AM ET\n\nAdd us on\n\nOn Monday, Singapore approved the COVID vaccine from U.S. vaccine maker Novavax for adults over age 18, making the city-state the latest country to give the go-ahead to Novavax’s protein-based jab.\n\nNovavax’s approval in Singapore follows a string of regulatory victories for the American firm, which has racked up approvals with the World Health Organization and [European Medicines Agency](https:\/\/fortune.com\/2021\/12\/20\/eu-bulks-up-its-arsenal-against-omicron-with-approval-of-novavax-vaccine-investors-dump-shares\/) and individual countries like [Australia](https:\/\/fortune.com\/2022\/01\/19\/novavax-covid-19-vaccine-gains-australia-approval-us\/), the U.K., and South Korea since late last year.\n\nSingapore’s government says it expects shipments of the jab to arrive within “the next few months.” It approved the jab based on clinical data that demonstrated up to 90% efficacy in preventing COVID-19 infections and 100% efficacy in preventing deaths. Singapore’s government said Novavax has not provided data on how the vaccine performs against Delta and Omicron variants, but it believes that the vaccine will continue to maintain efficacy against the more recent variants.\n\n“\\[Novavax’s\\] vaccine meets \\[Singapore’s\\] quality, safety, and efficacy standards, and the benefits outweigh the risks for the Singapore population,” a press release said.\n\nIn its vaccination drive, Singapore has deployed mRNA vaccines from Moderna and Pfizer as well as an inactivated jab from Chinese maker Sinovac. Singapore is also one of the [most vaccinated](https:\/\/fortune.com\/2022\/01\/19\/singapore-covid-19-cases-omicron-restrictions-travel-flights\/) countries in the world, with 84.8% of its population fully vaccinated and 57.6% of its population boosted. The U.S., by contrast, has fully vaccinated 63.8% of its population and boosted 27.3% of people, according to [Bloomberg](https:\/\/www.bloomberg.com\/graphics\/covid-vaccine-tracker-global-distribution\/).\n\nNovavax’s protein-based COVID jab works [slightly differently](https:\/\/www.sbs.com.au\/news\/why-novavax-is-different-to-other-vaccines-and-some-australians-have-held-out-for-it\/48be3d98-4f62-44b8-b224-81f6abd89c94) from the mRNA jabs of [Pfizer](https:\/\/fortune.com\/company\/pfizer\/) and [Moderna](https:\/\/fortune.com\/company\/moderna\/). Novavax’s vaccine inserts noninfectious spike proteins into the body to induce an immune response. The mRNA jabs teach the body to make its own spike proteins to ward off infections.\n\nManufacturing and regulatory delays [plagued](https:\/\/fortune.com\/2021\/09\/24\/novavax-who-approval-covid-vaccine-mrna-covax\/) Novavax for much of last year, but the company’s alternative, protein-based vaccine technology has nonetheless inspired [a group of fans](https:\/\/fortune.com\/2022\/01\/27\/novavax-fans-reddit-covid-vaccine-australia-us-approval\/) to wait to get the vaccine as a primary dose or booster shot, even though—in many cases—they’ve had access to other vaccines for months.\n\n“Despite high vaccination rates in Australia, there has been a demand for a protein-based formula,” Greg Hunt, Australia’s minister of health, said in a statement about rolling out [Novavax’s vaccine this week](https:\/\/www.health.gov.au\/ministers\/the-hon-greg-hunt-mp\/media\/novavax-first-protein-vaccine-now-available). “For some people, the arrival of Novavax will be the extra push they need to get their first jab and kick-start their protection against COVID-19.”\n\nIn the U.S., Novavax submitted its final paperwork to the Food and Drug Administration on Jan. 31, and Novavax CEO Stanley Erck recently said he expects [feedback from the FDA this month](https:\/\/www.cnbc.com\/2022\/01\/10\/novavax-ceo-covid-vaccine-could-be-cleared-in-multiple-countries-soon.html?utm_term=Autofeed&utm_medium=Social&utm_content=Main&utm_source=Twitter#Echobox=1641837029). Novavax also announced last Thursday that its vaccine proved 80% effective in a Phase III trial among 12- to 17-year-olds at a time when the Delta variant was dominant in the U.S., which may help the firm get its jab into the arms of younger populations.\n\n“We believe the Novavax vaccine offers a differentiated technology and option for this younger population given its established protein-based technology already used in other vaccines, and the positive responses demonstrated against variants,” Filip Dubovsky, Novavax’s chief medical officer, said in a [press release](https:\/\/ir.novavax.com\/2022-02-10-Novavax-Announces-Positive-Results-of-COVID-19-Vaccine-in-Pediatric-Population-of-PREVENT-19-Phase-3-Clinical-Trial).\n\nNever miss a story: [Follow your favorite topics and authors](https:\/\/fortune.com\/my-favorites\/) to get a personalized email with the journalism that matters most to you.\n\nAbout the Author\n\n[![Grady McGregor](https:\/\/content.fortune.com\/wp-content\/uploads\/2020\/09\/placeholder_16x9.jpg)](https:\/\/fortune.com\/author\/grady-mcgregor\/)\n\nBy [Grady McGregor](https:\/\/fortune.com\/author\/grady-mcgregor\/)\n\n[See full bio](https:\/\/fortune.com\/author\/grady-mcgregor\/)\n\nRankings\n\n- [100 Best Companies](https:\/\/fortune.com\/ranking\/best-companies\/)\n- [Fortune 500](https:\/\/fortune.com\/ranking\/fortune500\/)\n- [Global 500](https:\/\/fortune.com\/ranking\/global500\/)\n- [Fortune 500 Europe](https:\/\/fortune.com\/europe\/ranking\/fortune500-europe\/)\n- [Most Powerful Women](https:\/\/fortune.com\/ranking\/most-powerful-women\/)\n- [Future 50](https:\/\/fortune.com\/ranking\/future-50\/)\n- [World’s Most Admired Companies](https:\/\/fortune.com\/ranking\/worlds-most-admired-companies\/)\n- [See All Rankings](https:\/\/fortune.com\/ranking\/)\n\nSections\n\n- [Finance](https:\/\/fortune.com\/section\/finance\/)\n- [Fortune Crypto](https:\/\/fortune.com\/section\/crypto\/)\n- [Features](https:\/\/fortune.com\/section\/features\/)\n- [Leadership](https:\/\/fortune.com\/section\/leadership\/)\n- [Health](https:\/\/fortune.com\/section\/health\/)\n- [Commentary](https:\/\/fortune.com\/section\/commentary\/)\n- [Success](https:\/\/fortune.com\/section\/success\/)\n- [Retail](https:\/\/fortune.com\/section\/retail\/)\n- [Mpw](https:\/\/fortune.com\/section\/mpw\/)\n- [Tech](https:\/\/fortune.com\/section\/tech\/)\n- [Lifestyle](https:\/\/fortune.com\/section\/lifestyle\/)\n- [CEO Initiative](https:\/\/conferences.fortune.com\/event\/the-fortune-ceo-initiative-2026\/home)\n- [Asia](https:\/\/fortune.com\/section\/asia\/)\n- [Politics](https:\/\/fortune.com\/section\/politics\/)\n- [Conferences](https:\/\/fortune.com\/section\/conferences\/)\n- [Europe](https:\/\/fortune.com\/section\/europe\/)\n- [Newsletters](https:\/\/fortune.com\/section\/newsletters\/)\n- [Personal Finance](https:\/\/fortune.com\/section\/personal-finance\/)\n- [Environment](https:\/\/fortune.com\/section\/environment\/)\n- [Magazine](https:\/\/fortune.com\/section\/magazine\/)\n- [Education](https:\/\/fortune.com\/education\/)\n\nCustomer Support\n\n- [Frequently Asked Questions](https:\/\/fortunecustomerservice.zendesk.com\/hc\/en-us)\n- [Customer Service Portal](https:\/\/fortunecustomerservice.zendesk.com\/hc\/en-us)\n- [Privacy Policy](https:\/\/fortune.com\/privacy-policy\/)\n- [Terms Of Use](https:\/\/fortune.com\/terms-of-use\/)\n- [Single Issues For Purchase](https:\/\/order.emags.com\/fortune_single_issues)\n- [International Print](https:\/\/fortune.com\/international-print-magazine-only-subscribers\/)\n\nCommercial Services\n\n- [Advertising](https:\/\/fortune.com\/advertising\/)\n- [Fortune Brand Studio](https:\/\/fortune.com\/brandstudio\/fbs\/portfolio\/)\n- [Fortune Analytics](https:\/\/fortune.com\/analytics)\n- [Fortune Conferences](https:\/\/fortune.com\/conferences)\n- [Business Development](https:\/\/fortune.com\/business-development\/)\n- [Group Subscriptions](https:\/\/fortune.com\/group-subscriptions\/)\n\nAbout Us\n\n- [About Us](https:\/\/fortune.com\/about-us\/)\n- [Editorial Calendar](https:\/\/fortune.com\/editorial-calendar\/)\n- [Press Center](https:\/\/fortune.com\/press-center\/)\n- [Work At Fortune](https:\/\/fortune.wd108.myworkdayjobs.com\/en-US\/Fortune)\n- [Diversity And Inclusion](https:\/\/fortune.com\/workplace\/diversity-inclusion)\n- [Terms And Conditions](https:\/\/fortune.com\/terms-of-use\/)\n- [Site Map](https:\/\/fortune.com\/sitemap\/)\n\nRankings\n\nSections\n\nCustomer Support\n\nCommercial Services\n\n- [About Us](https:\/\/fortune.com\/about-us\/)\n- [Editorial Calendar](https:\/\/fortune.com\/editorial-calendar\/)\n- [Press Center](https:\/\/fortune.com\/press-center\/)\n- [Work At Fortune](https:\/\/fortune.wd108.myworkdayjobs.com\/en-US\/Fortune)\n- [Diversity And Inclusion](https:\/\/fortune.com\/workplace\/diversity-inclusion)\n- [Terms And Conditions](https:\/\/fortune.com\/terms-of-use\/)\n- [Site Map](https:\/\/fortune.com\/sitemap\/)\n\n© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our [Terms of Use](https:\/\/fortune.com\/terms-of-use\/) and [Privacy Policy](https:\/\/fortune.com\/privacy-policy\/) \\| [CA Notice at Collection and Privacy Notice](https:\/\/fortune.com\/california-privacy-policy\/#notice) \\| [Do Not Sell\/Share My Personal Information]()  \n FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.\n\n[search by queryly](https:\/\/www.queryly.com\/)\n\n[Advanced Search]()\n\n![close](https:\/\/www.queryly.com\/images\/whitecloseicon.png)\n\n![](https:\/\/www.facebook.com\/tr?id=2587034314640071&ev=PageView&noscript=1)","attrs_readable_markdown":"On Monday, Singapore approved the COVID vaccine from U.S. vaccine maker Novavax for adults over age 18, making the city-state the latest country to give the go-ahead to Novavax’s protein-based jab.\n\nNovavax’s approval in Singapore follows a string of regulatory victories for the American firm, which has racked up approvals with the World Health Organization and [European Medicines Agency](https:\/\/fortune.com\/2021\/12\/20\/eu-bulks-up-its-arsenal-against-omicron-with-approval-of-novavax-vaccine-investors-dump-shares\/) and individual countries like [Australia](https:\/\/fortune.com\/2022\/01\/19\/novavax-covid-19-vaccine-gains-australia-approval-us\/), the U.K., and South Korea since late last year.\n\nSingapore’s government says it expects shipments of the jab to arrive within “the next few months.” It approved the jab based on clinical data that demonstrated up to 90% efficacy in preventing COVID-19 infections and 100% efficacy in preventing deaths. Singapore’s government said Novavax has not provided data on how the vaccine performs against Delta and Omicron variants, but it believes that the vaccine will continue to maintain efficacy against the more recent variants.\n\n“\\[Novavax’s\\] vaccine meets \\[Singapore’s\\] quality, safety, and efficacy standards, and the benefits outweigh the risks for the Singapore population,” a press release said.\n\nIn its vaccination drive, Singapore has deployed mRNA vaccines from Moderna and Pfizer as well as an inactivated jab from Chinese maker Sinovac. Singapore is also one of the [most vaccinated](https:\/\/fortune.com\/2022\/01\/19\/singapore-covid-19-cases-omicron-restrictions-travel-flights\/) countries in the world, with 84.8% of its population fully vaccinated and 57.6% of its population boosted. The U.S., by contrast, has fully vaccinated 63.8% of its population and boosted 27.3% of people, according to [Bloomberg](https:\/\/www.bloomberg.com\/graphics\/covid-vaccine-tracker-global-distribution\/).\n\nNovavax’s protein-based COVID jab works [slightly differently](https:\/\/www.sbs.com.au\/news\/why-novavax-is-different-to-other-vaccines-and-some-australians-have-held-out-for-it\/48be3d98-4f62-44b8-b224-81f6abd89c94) from the mRNA jabs of [Pfizer](https:\/\/fortune.com\/company\/pfizer\/) and [Moderna](https:\/\/fortune.com\/company\/moderna\/). Novavax’s vaccine inserts noninfectious spike proteins into the body to induce an immune response. The mRNA jabs teach the body to make its own spike proteins to ward off infections.\n\nManufacturing and regulatory delays [plagued](https:\/\/fortune.com\/2021\/09\/24\/novavax-who-approval-covid-vaccine-mrna-covax\/) Novavax for much of last year, but the company’s alternative, protein-based vaccine technology has nonetheless inspired [a group of fans](https:\/\/fortune.com\/2022\/01\/27\/novavax-fans-reddit-covid-vaccine-australia-us-approval\/) to wait to get the vaccine as a primary dose or booster shot, even though—in many cases—they’ve had access to other vaccines for months.\n\n“Despite high vaccination rates in Australia, there has been a demand for a protein-based formula,” Greg Hunt, Australia’s minister of health, said in a statement about rolling out [Novavax’s vaccine this week](https:\/\/www.health.gov.au\/ministers\/the-hon-greg-hunt-mp\/media\/novavax-first-protein-vaccine-now-available). “For some people, the arrival of Novavax will be the extra push they need to get their first jab and kick-start their protection against COVID-19.”\n\nIn the U.S., Novavax submitted its final paperwork to the Food and Drug Administration on Jan. 31, and Novavax CEO Stanley Erck recently said he expects [feedback from the FDA this month](https:\/\/www.cnbc.com\/2022\/01\/10\/novavax-ceo-covid-vaccine-could-be-cleared-in-multiple-countries-soon.html?utm_term=Autofeed&utm_medium=Social&utm_content=Main&utm_source=Twitter#Echobox=1641837029). Novavax also announced last Thursday that its vaccine proved 80% effective in a Phase III trial among 12- to 17-year-olds at a time when the Delta variant was dominant in the U.S., which may help the firm get its jab into the arms of younger populations.\n\n“We believe the Novavax vaccine offers a differentiated technology and option for this younger population given its established protein-based technology already used in other vaccines, and the positive responses demonstrated against variants,” Filip Dubovsky, Novavax’s chief medical officer, said in a [press release](https:\/\/ir.novavax.com\/2022-02-10-Novavax-Announces-Positive-Results-of-COVID-19-Vaccine-in-Pediatric-Population-of-PREVENT-19-Phase-3-Clinical-Trial).","meta_canonical":null}

3. Robots.txt Check

Query:

Response:

4. Spam/Ban Check

Query:

Response:

5. Seen Status Check

ℹ️ Skipped - page is already crawled

📄

INDEXABLE

✅

CRAWLED

21 days ago

🤖

ROBOTS ALLOWED

Page Info Filters

Filter	Status	Condition	Details
HTTP status	PASS	`download_http_code = 200`	HTTP 200
Age cutoff	PASS	`download_stamp > now() - 6 MONTH`	0.7 months ago
History drop	PASS	`isNull(history_drop_reason)`	No drop reason
Spam/ban	PASS	`fh_dont_index != 1 AND ml_spam_score = 0`	ml_spam_score=0
Canonical	PASS	`meta_canonical IS NULL OR = '' OR = src_unparsed`	Not set

Page Details

Property	Value
URL	https://fortune.com/2022/02/14/novavax-covid-19-vaccine-approval-singapore-us-fda/
Last Crawled	2026-03-23 21:12:42 (21 days ago)
First Indexed	2022-02-14 07:39:53 (4 years ago)
HTTP Status Code	200
Meta Title	Singapore approves Novavax COVID vaccine while U.S. FDA reviews application \| Fortune
Meta Description	Singapore's green light adds to a string of approvals for the U.S.-based vaccine maker.
Meta Canonical	null
Boilerpipe Text	On Monday, Singapore approved the COVID vaccine from U.S. vaccine maker Novavax for adults over age 18, making the city-state the latest country to give the go-ahead to Novavax’s protein-based jab. Novavax’s approval in Singapore follows a string of regulatory victories for the American firm, which has racked up approvals with the World Health Organization and European Medicines Agency and individual countries like Australia , the U.K., and South Korea since late last year. Singapore’s government says it expects shipments of the jab to arrive within “the next few months.” It approved the jab based on clinical data that demonstrated up to 90% efficacy in preventing COVID-19 infections and 100% efficacy in preventing deaths. Singapore’s government said Novavax has not provided data on how the vaccine performs against Delta and Omicron variants, but it believes that the vaccine will continue to maintain efficacy against the more recent variants. “[Novavax’s] vaccine meets [Singapore’s] quality, safety, and efficacy standards, and the benefits outweigh the risks for the Singapore population,” a press release said. In its vaccination drive, Singapore has deployed mRNA vaccines from Moderna and Pfizer as well as an inactivated jab from Chinese maker Sinovac. Singapore is also one of the most vaccinated countries in the world, with 84.8% of its population fully vaccinated and 57.6% of its population boosted. The U.S., by contrast, has fully vaccinated 63.8% of its population and boosted 27.3% of people, according to Bloomberg . Novavax’s protein-based COVID jab works slightly differently from the mRNA jabs of Pfizer and Moderna . Novavax’s vaccine inserts noninfectious spike proteins into the body to induce an immune response. The mRNA jabs teach the body to make its own spike proteins to ward off infections. Manufacturing and regulatory delays plagued Novavax for much of last year, but the company’s alternative, protein-based vaccine technology has nonetheless inspired a group of fans to wait to get the vaccine as a primary dose or booster shot, even though—in many cases—they’ve had access to other vaccines for months. “Despite high vaccination rates in Australia, there has been a demand for a protein-based formula,” Greg Hunt, Australia’s minister of health, said in a statement about rolling out Novavax’s vaccine this week . “For some people, the arrival of Novavax will be the extra push they need to get their first jab and kick-start their protection against COVID-19.” In the U.S., Novavax submitted its final paperwork to the Food and Drug Administration on Jan. 31, and Novavax CEO Stanley Erck recently said he expects feedback from the FDA this month . Novavax also announced last Thursday that its vaccine proved 80% effective in a Phase III trial among 12- to 17-year-olds at a time when the Delta variant was dominant in the U.S., which may help the firm get its jab into the arms of younger populations. “We believe the Novavax vaccine offers a differentiated technology and option for this younger population given its established protein-based technology already used in other vaccines, and the positive responses demonstrated against variants,” Filip Dubovsky, Novavax’s chief medical officer, said in a press release .
Markdown	Search [Subscribe for \$1Subscribe for \$1](https://fortune.com/subscribe/?itm_source=Site_0_HCL_NAV_CTA_0_2025_ZZ&redirect=%2F2022%2F02%2F14%2Fnovavax-covid-19-vaccine-approval-singapore-us-fda%2F) [Sign in](https://fortune.com/signin/?signin_redirect=%2F2022%2F02%2F14%2Fnovavax-covid-19-vaccine-approval-singapore-us-fda%2F) - [Home](https://fortune.com/) - [Latest](https://fortune.com/section/latest/) - [Fortune 500](https://fortune.com/section/fortune-500/) - [Finance](https://fortune.com/section/finance/) - [Tech](https://fortune.com/section/tech/) - [Leadership](https://fortune.com/section/leadership/) - [Lifestyle](https://fortune.com/section/lifestyle/) - [Rankings](https://fortune.com/ranking/) - [Multimedia](https://fortune.com/2022/02/14/novavax-covid-19-vaccine-approval-singapore-us-fda/) [COVID-19 vaccines](https://fortune.com/tag/covid-vaccine/) # Singapore is the latest country to approve Novavax’s COVID vaccine while the U.S. reviews application ![Grady McGregor](https://content.fortune.com/wp-content/uploads/2020/09/placeholder_16x9.jpg) By [Grady McGregor](https://fortune.com/author/grady-mcgregor/) Grady McGregor ![Grady McGregor](https://content.fortune.com/wp-content/uploads/2020/09/placeholder_16x9.jpg) By [Grady McGregor](https://fortune.com/author/grady-mcgregor/) Grady McGregor February 14, 2022, 1:36 AM ET Add us on On Monday, Singapore approved the COVID vaccine from U.S. vaccine maker Novavax for adults over age 18, making the city-state the latest country to give the go-ahead to Novavax’s protein-based jab. Novavax’s approval in Singapore follows a string of regulatory victories for the American firm, which has racked up approvals with the World Health Organization and [European Medicines Agency](https://fortune.com/2021/12/20/eu-bulks-up-its-arsenal-against-omicron-with-approval-of-novavax-vaccine-investors-dump-shares/) and individual countries like [Australia](https://fortune.com/2022/01/19/novavax-covid-19-vaccine-gains-australia-approval-us/), the U.K., and South Korea since late last year. Singapore’s government says it expects shipments of the jab to arrive within “the next few months.” It approved the jab based on clinical data that demonstrated up to 90% efficacy in preventing COVID-19 infections and 100% efficacy in preventing deaths. Singapore’s government said Novavax has not provided data on how the vaccine performs against Delta and Omicron variants, but it believes that the vaccine will continue to maintain efficacy against the more recent variants. “\[Novavax’s\] vaccine meets \[Singapore’s\] quality, safety, and efficacy standards, and the benefits outweigh the risks for the Singapore population,” a press release said. In its vaccination drive, Singapore has deployed mRNA vaccines from Moderna and Pfizer as well as an inactivated jab from Chinese maker Sinovac. Singapore is also one of the [most vaccinated](https://fortune.com/2022/01/19/singapore-covid-19-cases-omicron-restrictions-travel-flights/) countries in the world, with 84.8% of its population fully vaccinated and 57.6% of its population boosted. The U.S., by contrast, has fully vaccinated 63.8% of its population and boosted 27.3% of people, according to [Bloomberg](https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/). Novavax’s protein-based COVID jab works [slightly differently](https://www.sbs.com.au/news/why-novavax-is-different-to-other-vaccines-and-some-australians-have-held-out-for-it/48be3d98-4f62-44b8-b224-81f6abd89c94) from the mRNA jabs of [Pfizer](https://fortune.com/company/pfizer/) and [Moderna](https://fortune.com/company/moderna/). Novavax’s vaccine inserts noninfectious spike proteins into the body to induce an immune response. The mRNA jabs teach the body to make its own spike proteins to ward off infections. Manufacturing and regulatory delays [plagued](https://fortune.com/2021/09/24/novavax-who-approval-covid-vaccine-mrna-covax/) Novavax for much of last year, but the company’s alternative, protein-based vaccine technology has nonetheless inspired [a group of fans](https://fortune.com/2022/01/27/novavax-fans-reddit-covid-vaccine-australia-us-approval/) to wait to get the vaccine as a primary dose or booster shot, even though—in many cases—they’ve had access to other vaccines for months. “Despite high vaccination rates in Australia, there has been a demand for a protein-based formula,” Greg Hunt, Australia’s minister of health, said in a statement about rolling out [Novavax’s vaccine this week](https://www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/novavax-first-protein-vaccine-now-available). “For some people, the arrival of Novavax will be the extra push they need to get their first jab and kick-start their protection against COVID-19.” In the U.S., Novavax submitted its final paperwork to the Food and Drug Administration on Jan. 31, and Novavax CEO Stanley Erck recently said he expects [feedback from the FDA this month](https://www.cnbc.com/2022/01/10/novavax-ceo-covid-vaccine-could-be-cleared-in-multiple-countries-soon.html?utm_term=Autofeed&utm_medium=Social&utm_content=Main&utm_source=Twitter#Echobox=1641837029). Novavax also announced last Thursday that its vaccine proved 80% effective in a Phase III trial among 12- to 17-year-olds at a time when the Delta variant was dominant in the U.S., which may help the firm get its jab into the arms of younger populations. “We believe the Novavax vaccine offers a differentiated technology and option for this younger population given its established protein-based technology already used in other vaccines, and the positive responses demonstrated against variants,” Filip Dubovsky, Novavax’s chief medical officer, said in a [press release](https://ir.novavax.com/2022-02-10-Novavax-Announces-Positive-Results-of-COVID-19-Vaccine-in-Pediatric-Population-of-PREVENT-19-Phase-3-Clinical-Trial). Never miss a story: [Follow your favorite topics and authors](https://fortune.com/my-favorites/) to get a personalized email with the journalism that matters most to you. About the Author [![Grady McGregor](https://content.fortune.com/wp-content/uploads/2020/09/placeholder_16x9.jpg)](https://fortune.com/author/grady-mcgregor/) By [Grady McGregor](https://fortune.com/author/grady-mcgregor/) [See full bio](https://fortune.com/author/grady-mcgregor/) Rankings - [100 Best Companies](https://fortune.com/ranking/best-companies/) - [Fortune 500](https://fortune.com/ranking/fortune500/) - [Global 500](https://fortune.com/ranking/global500/) - [Fortune 500 Europe](https://fortune.com/europe/ranking/fortune500-europe/) - [Most Powerful Women](https://fortune.com/ranking/most-powerful-women/) - [Future 50](https://fortune.com/ranking/future-50/) - [World’s Most Admired Companies](https://fortune.com/ranking/worlds-most-admired-companies/) - [See All Rankings](https://fortune.com/ranking/) Sections - [Finance](https://fortune.com/section/finance/) - [Fortune Crypto](https://fortune.com/section/crypto/) - [Features](https://fortune.com/section/features/) - [Leadership](https://fortune.com/section/leadership/) - [Health](https://fortune.com/section/health/) - [Commentary](https://fortune.com/section/commentary/) - [Success](https://fortune.com/section/success/) - [Retail](https://fortune.com/section/retail/) - [Mpw](https://fortune.com/section/mpw/) - [Tech](https://fortune.com/section/tech/) - [Lifestyle](https://fortune.com/section/lifestyle/) - [CEO Initiative](https://conferences.fortune.com/event/the-fortune-ceo-initiative-2026/home) - [Asia](https://fortune.com/section/asia/) - [Politics](https://fortune.com/section/politics/) - [Conferences](https://fortune.com/section/conferences/) - [Europe](https://fortune.com/section/europe/) - [Newsletters](https://fortune.com/section/newsletters/) - [Personal Finance](https://fortune.com/section/personal-finance/) - [Environment](https://fortune.com/section/environment/) - [Magazine](https://fortune.com/section/magazine/) - [Education](https://fortune.com/education/) Customer Support - [Frequently Asked Questions](https://fortunecustomerservice.zendesk.com/hc/en-us) - [Customer Service Portal](https://fortunecustomerservice.zendesk.com/hc/en-us) - [Privacy Policy](https://fortune.com/privacy-policy/) - [Terms Of Use](https://fortune.com/terms-of-use/) - [Single Issues For Purchase](https://order.emags.com/fortune_single_issues) - [International Print](https://fortune.com/international-print-magazine-only-subscribers/) Commercial Services - [Advertising](https://fortune.com/advertising/) - [Fortune Brand Studio](https://fortune.com/brandstudio/fbs/portfolio/) - [Fortune Analytics](https://fortune.com/analytics) - [Fortune Conferences](https://fortune.com/conferences) - [Business Development](https://fortune.com/business-development/) - [Group Subscriptions](https://fortune.com/group-subscriptions/) About Us - [About Us](https://fortune.com/about-us/) - [Editorial Calendar](https://fortune.com/editorial-calendar/) - [Press Center](https://fortune.com/press-center/) - [Work At Fortune](https://fortune.wd108.myworkdayjobs.com/en-US/Fortune) - [Diversity And Inclusion](https://fortune.com/workplace/diversity-inclusion) - [Terms And Conditions](https://fortune.com/terms-of-use/) - [Site Map](https://fortune.com/sitemap/) Rankings Sections Customer Support Commercial Services - [About Us](https://fortune.com/about-us/) - [Editorial Calendar](https://fortune.com/editorial-calendar/) - [Press Center](https://fortune.com/press-center/) - [Work At Fortune](https://fortune.wd108.myworkdayjobs.com/en-US/Fortune) - [Diversity And Inclusion](https://fortune.com/workplace/diversity-inclusion) - [Terms And Conditions](https://fortune.com/terms-of-use/) - [Site Map](https://fortune.com/sitemap/) © 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our [Terms of Use](https://fortune.com/terms-of-use/) and [Privacy Policy](https://fortune.com/privacy-policy/) \\| [CA Notice at Collection and Privacy Notice](https://fortune.com/california-privacy-policy/#notice) \\| [Do Not Sell/Share My Personal Information]() FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice. [search by queryly](https://www.queryly.com/) [Advanced Search]() ![close](https://www.queryly.com/images/whitecloseicon.png) ![](https://www.facebook.com/tr?id=2587034314640071&ev=PageView&noscript=1)
Readable Markdown	On Monday, Singapore approved the COVID vaccine from U.S. vaccine maker Novavax for adults over age 18, making the city-state the latest country to give the go-ahead to Novavax’s protein-based jab. Novavax’s approval in Singapore follows a string of regulatory victories for the American firm, which has racked up approvals with the World Health Organization and [European Medicines Agency](https://fortune.com/2021/12/20/eu-bulks-up-its-arsenal-against-omicron-with-approval-of-novavax-vaccine-investors-dump-shares/) and individual countries like [Australia](https://fortune.com/2022/01/19/novavax-covid-19-vaccine-gains-australia-approval-us/), the U.K., and South Korea since late last year. Singapore’s government says it expects shipments of the jab to arrive within “the next few months.” It approved the jab based on clinical data that demonstrated up to 90% efficacy in preventing COVID-19 infections and 100% efficacy in preventing deaths. Singapore’s government said Novavax has not provided data on how the vaccine performs against Delta and Omicron variants, but it believes that the vaccine will continue to maintain efficacy against the more recent variants. “\[Novavax’s\] vaccine meets \[Singapore’s\] quality, safety, and efficacy standards, and the benefits outweigh the risks for the Singapore population,” a press release said. In its vaccination drive, Singapore has deployed mRNA vaccines from Moderna and Pfizer as well as an inactivated jab from Chinese maker Sinovac. Singapore is also one of the [most vaccinated](https://fortune.com/2022/01/19/singapore-covid-19-cases-omicron-restrictions-travel-flights/) countries in the world, with 84.8% of its population fully vaccinated and 57.6% of its population boosted. The U.S., by contrast, has fully vaccinated 63.8% of its population and boosted 27.3% of people, according to [Bloomberg](https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/). Novavax’s protein-based COVID jab works [slightly differently](https://www.sbs.com.au/news/why-novavax-is-different-to-other-vaccines-and-some-australians-have-held-out-for-it/48be3d98-4f62-44b8-b224-81f6abd89c94) from the mRNA jabs of [Pfizer](https://fortune.com/company/pfizer/) and [Moderna](https://fortune.com/company/moderna/). Novavax’s vaccine inserts noninfectious spike proteins into the body to induce an immune response. The mRNA jabs teach the body to make its own spike proteins to ward off infections. Manufacturing and regulatory delays [plagued](https://fortune.com/2021/09/24/novavax-who-approval-covid-vaccine-mrna-covax/) Novavax for much of last year, but the company’s alternative, protein-based vaccine technology has nonetheless inspired [a group of fans](https://fortune.com/2022/01/27/novavax-fans-reddit-covid-vaccine-australia-us-approval/) to wait to get the vaccine as a primary dose or booster shot, even though—in many cases—they’ve had access to other vaccines for months. “Despite high vaccination rates in Australia, there has been a demand for a protein-based formula,” Greg Hunt, Australia’s minister of health, said in a statement about rolling out [Novavax’s vaccine this week](https://www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/novavax-first-protein-vaccine-now-available). “For some people, the arrival of Novavax will be the extra push they need to get their first jab and kick-start their protection against COVID-19.” In the U.S., Novavax submitted its final paperwork to the Food and Drug Administration on Jan. 31, and Novavax CEO Stanley Erck recently said he expects [feedback from the FDA this month](https://www.cnbc.com/2022/01/10/novavax-ceo-covid-vaccine-could-be-cleared-in-multiple-countries-soon.html?utm_term=Autofeed&utm_medium=Social&utm_content=Main&utm_source=Twitter#Echobox=1641837029). Novavax also announced last Thursday that its vaccine proved 80% effective in a Phase III trial among 12- to 17-year-olds at a time when the Delta variant was dominant in the U.S., which may help the firm get its jab into the arms of younger populations. “We believe the Novavax vaccine offers a differentiated technology and option for this younger population given its established protein-based technology already used in other vaccines, and the positive responses demonstrated against variants,” Filip Dubovsky, Novavax’s chief medical officer, said in a [press release](https://ir.novavax.com/2022-02-10-Novavax-Announces-Positive-Results-of-COVID-19-Vaccine-in-Pediatric-Population-of-PREVENT-19-Phase-3-Clinical-Trial).
Shard	79 (laksa)
Root Hash	13809836321913650279
Unparsed URL	com,fortune!/2022/02/14/novavax-covid-19-vaccine-approval-singapore-us-fda/ s443